Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Surachat Ngorsuraches & Nabin Poudel. (2021) Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 183-195.
Read now
Read now
Oscar Fernández, Miguel Angel Calleja-Hernández, José Meca-Lallana, Celia Oreja-Guevara, Ana Polanco & Ferran Pérez-Alcántara. (2017) Estimate of the cost of multiple sclerosis in Spain by literature review. Expert Review of Pharmacoeconomics & Outcomes Research 17:4, pages 321-333.
Read now
Read now
Josep Darbà, Lisette Kaskens & Rainel Sánchez-de la Rosa. (2014) Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study. Journal of Medical Economics 17:3, pages 215-222.
Read now
Read now
Ángel Sanz Granda, Laura García Jurado & Carlos Polanco Sánchez. (2012) Letter to the editor. Journal of Medical Economics 15:6, pages 1051-1053.
Read now
Read now
Articles from other publishers (13)
Anggie Wiyani, Lohit Badgujar, Vivek Khurana & Nicholas Adlard. (2021) How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review. Neurology and Therapy 10:2, pages 557-583.
Crossref
Crossref
Natalie A Schwehr, Karen M Kuntz, Mary Butler, Eva A Enns, Nathan D Shippee, Elaine Kingwell, Helen Tremlett & Adam F Carpenter. (2019) Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis. Multiple Sclerosis Journal 26:12, pages 1510-1518.
Crossref
Crossref
Natalie A. Schwehr, Karen M. Kuntz, Eva A. Enns, Nathan D. Shippee, Elaine Kingwell, Helen Tremlett, Adam F. Carpenter & Mary Butler. (2020) Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis. Drugs & Aging 37:3, pages 225-235.
Crossref
Crossref
Luis Hernandez, Malinda O’Donnell & Maarten Postma. (2018) Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations. PharmacoEconomics 36:10, pages 1223-1252.
Crossref
Crossref
Sergio Iannazzo, Ange-Christelle Iliza & Louise Perrault. (2017) Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies. PharmacoEconomics 36:2, pages 189-204.
Crossref
Crossref
GJ Melendez-Torres, Peter Auguste, Xavier Armoiry, Hendramoorthy Maheswaran, Rachel Court, Jason Madan, Alan Kan, Stephanie Lin, Carl Counsell, Jacoby Patterson, Jeremy Rodrigues, Olga Ciccarelli, Hannah Fraser & Aileen Clarke. (2017) Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technology Assessment 21:52, pages 1-352.
Crossref
Crossref
Erkki Soini, Jaana Joutseno & Marja-Liisa Sumelahti. (2017) Cost-utility of First-line Disease-modifying Treatments for Relapsing–Remitting Multiple Sclerosis. Clinical Therapeutics 39:3, pages 537-557.e10.
Crossref
Crossref
Rainel Sánchez-de la Rosa, Laura García-Bujalance & José Meca-Lallana. (2015) Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study. Health Economics Review 5:1.
Crossref
Crossref
Livio Garattini, Francesca Ghislandi & Milene Rangel Da Costa. (2015) Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?. PharmacoEconomics 33:12, pages 1241-1244.
Crossref
Crossref
Shien Guo, Christopher Pelligra, Catherine Saint-Laurent Thibault, Luis Hernandez & Anuraag Kansal. (2014) Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches. PharmacoEconomics 32:6, pages 559-572.
Crossref
Crossref
Miguel A. Mac?as-Islas, Isaac F. Soria-Cedillo, Merced Velazquez-Quintana, Victor M. Rivera, Ver?nica I. Baca-Muro, Edith A. Lemus-Carmona & Erwin Chiquete. (2013) Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis. Acta Neurologica Belgica 113:4, pages 415-420.
Crossref
Crossref
Sanober Nusrat, David Levinthal & Klaus Bielefeldt. (2013) Hospitalization Rates and Discharge Status in Multiple Sclerosis. Multiple Sclerosis International 2013, pages 1-7.
Crossref
Crossref
Oscar Fernández. (2012) Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis. Journal of Central Nervous System Disease 4, pages JCNSD.S8755.
Crossref
Crossref